Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

William Guyer's pre-scheduled disposition under a Rule 10b5-1 plan liquidates some direct holdings while retaining 130,000 derivative securities.

CryptoAlerta — análise de criptomoedas e mercado em tempo real